Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewVU 0361737
Discontinued Product
3707 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.
Description: Selective positive allosteric modulator of mGlu4 receptors
Chemical Name: N-(4-Chloro-3-methoxyphenyl)-2-pyridinecarboxamide
Purity: ≥99% (HPLC)
Biological Activity for VU 0361737
VU 0361737 is a selective positive allosteric modulator at mGlu4 receptors (EC50 values are 240 and 110 nM at human and rat receptors respectively). Inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors and displays weak activity at mGlu5 and mGlu8 receptors. Brain penetrant.
Technical Data for VU 0361737
| M. Wt | 262.69 |
| Formula | C13H11ClN2O2 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 1161205-04-4 |
| PubChem ID | 44191096 |
| InChI Key | ARYUXFNGXHNNDM-UHFFFAOYSA-N |
| Smiles | ClC1=C(OC)C=C(NC(C2=NC=CC=C2)=O)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for VU 0361737
References for VU 0361737
References are publications that support the biological activity of the product.
Engers et al (2009) Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J.Med.Chem. 52 4115 PMID: 19469556
Engers et al (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-(4-Acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu4) with CNS exposure in rats. J.Med.Chem. 54 1106 PMID: 21247167
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group III Receptor Modulators
Keywords: VU 0361737, VU 0361737 supplier, Selective, positive, allosteric, modulators, mGlu4, mGluR4, group, III, metabotropic, glutamate, receptors, VU0361737, PAM, Glutamate, (Metabotropic), Group, Receptors, 3707, Tocris Bioscience
1 Citation for VU 0361737
Citations are publications that use Tocris products. Selected citations for VU 0361737 include:
Jones et al (2011) Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 ( J Med Chem 54 7639 PMID: 21966889
Reviews for VU 0361737
There are currently no reviews for this product. Be the first to review VU 0361737 and earn rewards!
Have you used VU 0361737?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.